GLP1R and Hypoglycemia: SGLT2-I and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) would seem to be the solution to this problem, as they reduce the risk of hypoglycemia and have cardioprotective pleiotropic effects not only in the cardiovascular prevention, but also in acute conditions, such as ACS [56].